scholarly journals Prothrombotic risk factors in patients with recurrent thrombosis of the arteriovenous fistula

2006 ◽  
Vol 35 (11) ◽  
pp. 715-730
Author(s):  
Betul Tavil ◽  
Ayşin Bakkaloglu ◽  
Aytemiz Gurgey
Keyword(s):  
Risk Factors ◽  
Arteriovenous Fistula ◽  
Recurrent Thrombosis ◽  
Prothrombotic Risk Factors

The impact of inherited prothrombotic risk factors on individuals chronically infected with hepatitis C virus from a single source

2007 ◽  
Vol 14 (4) ◽  
pp. 255-259 ◽  
Author(s):  
C. Goulding ◽  
C. O'Brien ◽  
H. Egan ◽  
J. E. Hegarty ◽  
G. McDonald ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Single Source ◽  
Prothrombotic Risk Factors ◽  
The Impact

Diagnostic Studies for Thrombophilia in Women on Hormonal Therapy and During Pregnancy, and in Children

2002 ◽  
Vol 126 (11) ◽  
pp. 1296-1303
Author(s):  
Benjamin R. Brenner ◽  
Ulrike Nowak-Göttl ◽  
Andrea Kosch ◽  
Marilyn Manco-Johnson ◽  
Michael Laposata
Keyword(s):  
Risk Factors ◽  
Clinical Practice ◽  
Oral Contraceptive ◽  
Medical Literature ◽  
Data Extraction ◽  
Data Sources ◽  
Current Clinical Practice ◽  
Extensive Review ◽  
Prothrombotic Risk Factors

Abstract Objective.—To review the role of acquired and inherited prothrombotic risk factors that increase the risk of thrombosis in oral contraceptive users, during pregnancy, and in neonates, infants, and children; and to determine by the consensus opinion of recognized experts in the field which risk factors should be determined in which individuals at which time. Data Sources.—Review of the medical literature and current clinical practice by a panel of experts in the field of thrombophilia. Data Extraction and Synthesis.—The experts made an extensive review of the published literature and prepared a draft manuscript, which included preliminary recommendations. The draft manuscript was circulated to participants in the College of American Pathologists Conference XXXVI: Diagnostic Issues in Thrombophilia prior to the conference. The manuscript and recommendations were then presented at the conference for discussion. Recommendations were accepted if a consensus of the 26 experts attending the conference was reached. The results of the discussion were used to revise the manuscript into its final form. Conclusions.—This report reviews the options for testing for thrombophilic states in women using oral contraceptives, during pregnancy, and in neonates and children. General guidelines for testing in these clinical situations are provided, along with citation of the appropriate supporting literature.

Preoperative noninvasive artery flow volume and maturation of arteriovenous fistulae: A single surgeon’s experience from 403 cases

2019 ◽  
Vol 21 (4) ◽  
pp. 434-439
Author(s):  
George Blessios ◽  
Alexander Hlepas ◽  
Alonso Diaz
Keyword(s):  
Risk Factors ◽  
Arteriovenous Fistula ◽  
Doppler Ultrasound ◽  
Significant Risk ◽  
Flow Volume ◽  
Arterial Diameter ◽  
Ultrasound Evaluation ◽  
Maturation Rate ◽  
Fistula Maturation ◽  
Arteriovenous Fistula Maturation

Background: Preoperative Doppler ultrasound evaluation of arteriovenous fistula inflow artery includes measurements of arterial diameter and flow volume. The purpose of this study was to evaluate the significance of flow volume to arteriovenous fistula maturation rate. Study design: Review of consecutive patients who underwent arteriovenous fistula creation by a single surgeon. Cases with available preoperative arterial diameter and flow volume were analyzed. Primary end point was arteriovenous fistula failure to mature. Information collected included demographics, Doppler ultrasound reports, level of inflow artery, operative reports, and outcomes to the time of arteriovenous fistula maturation or failure. Risk factors were identified by logistic regression analysis. Outcomes were compared by odds ratio. Results: Four hundred and three cases were identified. Arterial diameter and flow volume were both independent significant risk factors affecting arteriovenous fistula maturation rate (p = 0.001). Arterial diameter of <2.5 mm and flow volume of <20 mL/min predicted failure to mature with 95% specificity. Further comparison of cases with optimal arterial diameter but flow volume of <20 mL/min showed increased failure to mature rate compared to the combination of optimal arterial diameter with optimal flow volume (p = 0.01) Conclusion: Preoperative arterial diameter and flow volume values were both significant independent variables affecting arteriovenous fistula maturation rate. However, flow volume of <20 mL/min remained a significant risk factor to failure-to-mature rate, despite optimal arterial diameter.

Lipoprotein (a) and other prothrombotic risk factors in Caucasian women with unexplained recurrent miscarriage

2005 ◽  
Vol 93 (05) ◽  
pp. 867-871 ◽  
Author(s):  
Manuela Krause ◽  
Barbara Sonntag ◽  
Robert Klamroth ◽  
Achim Heinecke ◽  
Carola Scholz ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Recurrent Miscarriage ◽  
Univariate Analysis ◽  
Plasminogen Activator Inhibitor ◽  
Protein S ◽  
Factor V ◽  
Prothrombotic Risk Factors ◽  
Caucasian Women ◽  
Unexplained Recurrent Miscarriage

SummaryFrom 1998 to 2003, 133 Caucasian women aged 17–40 years (median 29 years) suffering from unexplained recurrent miscarriage (uRM) were consecutively enrolled. In patients and 133 age-matched healthy controls prothrombotic risk factors (factor V (FV) G1691A, factor II (FII) G20210A, MTHFR T677T, 4G/5G plasminogen activator inhibitor (PAI)-1, lipoprotein (Lp) (a), protein C (PC), protein S (PS), antithrombin (AT), antiphospholipid/anticardiolipin (APA/ACA) antibodies) as well as associated environmental conditions (smoking and obesity) were investigated. 70 (52.6%) of the patients had at least one prothrombotic risk factor compared with 26 control women (19.5%; p<0.0001). Body mass index (BMI; p=0.78) and smoking habits (p=0.44) did not differ significantly between the groups investigated. Upon univariate analysis the heterozygous FV mutation, Lp(a) > 30 mg/dL, increased APA/ACA and BMI > 25 kg/m2 in combination with a prothrombotic risk factor were found to be significantly associated with uRM. In multivariate analysis, increased Lp(a) (odds ratio (OR): 4.7/95% confidence interval (CI): 2.0–10.7), the FV mutation (OR:3.8/CI:1.4–10.7), and increased APA/ACA (OR: 4.5/CI: 1.1–17.7) had independent associations with uRM.

Risk Factors for Recurrent Thrombosis: Prospective Study of a Cohort of Japanese Systemic Lupus Erythematosus

Angiology ◽  
2005 ◽  
Vol 56 (5) ◽  
pp. 601-609 ◽  
Author(s):  
Tomohiro Akimoto ◽  
Shigeto Kobayashi ◽  
Naoto Tamura ◽  
Toshiya Ohsawa ◽  
Terunaga Kawano ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systemic Lupus Erythematosus ◽  
Prospective Study ◽  
Lupus Erythematosus ◽  
Recurrent Thrombosis ◽  
Systemic Lupus

INHERITED PROTHROMBOTIC RISK FACTORS IN CHILDREN WITH CEREBROVASCULAR DISORDERS

2007 ◽  
Vol 5 ◽  
pp. P-W-584-P-W-584
Author(s):  
R. Zadro ◽  
D. Coen Herak ◽  
M. Radic Antolic ◽  
A. Basnec Brkic ◽  
J. Lenicek-Krleza ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cerebrovascular Disorders ◽  
Prothrombotic Risk Factors

scholarly journals Prothrombin G20210A Gene Mutation and Further Prothrombotic Risk Factors in Childhood Thrombophilia

1999 ◽  
Vol 19 (10) ◽  
pp. 2568-2572 ◽  
Author(s):  
Ralf Junker ◽  
Hans-Georg Koch ◽  
Karin Auberger ◽  
Nicole Münchow ◽  
Silke Ehrenforth ◽  
...  
Keyword(s):  
Risk Factors ◽  
Gene Mutation ◽  
Prothrombin G20210a ◽  
Prothrombotic Risk Factors

Inherited prothrombotic risk factors in children with hereditary angioedema

2019 ◽  
pp. 1
Author(s):  
Murat Cansever ◽  
Alper Ozcan ◽  
Yusuf Ozkul ◽  
Turkan Patiroglu
Keyword(s):  
Risk Factors ◽  
Hereditary Angioedema ◽  
Prothrombotic Risk Factors

Thrombophylic Profile of Fabry Patients in Argentina.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4048-4048
Author(s):  
Mario C. Aggio ◽  
Pablo A. Martinez
Keyword(s):  
Risk Factors ◽  
Gaucher Disease ◽  
Protein C ◽  
Activated Protein C ◽  
Protein S ◽  
Anticardiolipin Antibodies ◽  
Nutritional Deficiencies ◽  
Lysosomal Storage ◽  
Metabolic Disturbances ◽  
Prothrombotic Risk Factors

Abstract Anderson-Fabry disease (AFD), described independently in the 1890s by William Anderson and Johann Fabry, is the second most frequent lysosomal storage disorder (after Gaucher disease). AFD is a pan-ethnic disorder due to a deficiency of the lysosomal enzime alpha-galactosidase A (alpha-GAL), with an estimated frequency of 1 in 117,000 male births, although recent studies suggest that the incidence may be underestimated, as certain patients with residual alpha-GAL activity (5 to 35% of normal levels) have disease too. Increased incidence of thrombotic events has been demonstrated in AFD. We evaluated the prevalence of prothrombotic risk factors in Argentine patients. Patients/methods: 36 patients (15 hemizygous and 21 heterozygous from 3 families) were studied for: protein C pathway (PCSys), antithrombin (AT), protein C (PC), protein S (PS), activated protein C resistance (APCR), lupus anticoagulant (LA), total plasma homocysteine (tHcy), anticardiolipin antibodies (ACA), and antiphosphatidylserine antibodies (APA). Results: The evaluation of PCSys, APCR, plasmatic levels of PC, PS, AT and APA were normal in all patients. Elevated levels of tHcy were found in 19.4% (n=7). Positive for LA were 38.9% (n=14) and for ACA 8.3% (n=3). Conclusions: 1) Our results confirm data from the literature reporting elevated homocysteinemia in AFD patients. Nutritional deficiencies, renal failure and metabolic disturbances are probable etiologic factors. 2) Thrombophilia was more frequent in hemizygous (13 patients, 86.7%) than in heterozygous (8 patients, 38.1%). Four hemizygous patients showed coexistence of two risk factors. 3) We found an unexpected high incidence of procoagulant autoantibodies. This association has also been reported and might contribute to thrombophilia in AFD: as in Gaucher disease, the accumulation of immunogenic glucocerebrosides might induce chronic immunostimulation.

European Collaborative Paediatric Database on Cerebral Venous Thrombosis: Risk Factors for Recurrent Venous Thromboembolism.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 276-276
Author(s):  
Gili Kenet ◽  
Fenella Kirkham ◽  
Thomas Niederstadt ◽  
Karin Kurnik ◽  
Rosemarie Schobess ◽  
...  
Keyword(s):  
Risk Factors ◽  
Venous Thrombosis ◽  
Cerebral Venous Thrombosis ◽  
Cox Regression ◽  
Treatment Guidelines ◽  
Cox Regression Analysis ◽  
G20210a Mutation ◽  
Thrombosis Risk ◽  
Factor Ii ◽  
Prothrombotic Risk Factors

Abstract Background: Risk factors for cerebral venous thrombosis (CVT) in children include local and systemic underlying conditions, drug toxicity, and hereditary prothrombotic risk factors. Their relevance to the risk of a second venous thrombosis (VT), compared with other clinical, neuroimaging and treatment variables, is unknown. Methods: 330 of 407 consecutively enrolled CVT-patients aged newborn to <18 years (median 5.3 years; male 55%) were prospectively followed for a median (range) of 33 (12–84) months. In accordance to international treatment guidelines, 259 children (78.5%) received acute antithrombotic therapy (AT) with UFH or LMWH, followed by long-term AT with LMWH or warfarin in 218 cases (66.0%). Findings: Recurrent VT was diagnosed in 19 of 330 children (5.8%) at a median (range) age of 6 (0.5–84) months following CVT, with no difference observed between the study centres (p=0.84). Multivariate Cox regression analysis revealed that the risk of recurrence was significantly higher in those with older age at first CVT onset (p=0.02), those in whom AT was not administered prior to recurrence (p=0.0003), those who did not have complete patency rates on repeat venography at 3–6 months (p=0.01), and those subjects carrying the factor II G20210A mutation (p=0.03). Interpretation: Age at CVT onset, administration of AT, poor patency rates, and the factor II G20210A variant were of relevance to recurrent VT in children with CVT. Until evidence-based data derived from randomized treatment trials are available the message of this follow-up study is to administer any AT prophylaxis on an individual patient basis in paediatric CVT cases in newly identified VT risk situations.

Sign in / Sign up

Export Citation Format

Share Document